<DOC>
	<DOCNO>NCT02469974</DOCNO>
	<brief_summary>To determine safety approach give RUXOLITINIB autologous stem cell transplant , measure graft failure death .</brief_summary>
	<brief_title>Ruxolitinib Combination With Autotransplant</brief_title>
	<detailed_description>This pilot , single arm , single center study stratification ass safety ( measure graft failure death ) feasibility ( measure adequacy stem cell collection ) combine ruxolitinib autologous Hematopoeitic Stem Cell Transplantation ( HSCT ) patient advanced myelofibrosis ( MF ) . Patients receive short course ruxolitinib prior mobilization HSCT Filgrastim . Conditioning autologous HSCT consist Bulsulfan . Post-transplant patient receive ruxolitinib maintenance .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Histologically document diagnosis MF ( idiopathic post PV/ET ) Age 1875 year Intermediate2/ highrisk disease per Dynamic IPSS ( DIPSS ) criteria Intermediate1 risk disease one following feature within one year screening : 1 . Red cell transfusion dependency 2. unfavorable Karyotype 3. platelet count &lt; 100 x 109/L 4. symptomatic splenomegaly 5 . PB blast &gt; 1 % 6 . Blasts PB &lt; 20 % prior study enrollment 7 . No available suitable match relate ( 6/6 5/6 ) unrelated donor ( 8/8 7/8 allele match ) unwilling unable pursue allogeneic stem cell transplant 8 . WBC &lt; 50,000/ml screen Able give inform write consent ECOG Performance status 02 Life expectancy &gt; 6 month Off myelofibrosisrelated investigational standard agent ( except ruxolitinib ) least 4 week prior study enrollment recover toxicity . If patient already ruxolitinib minimum 16 week prior study enrollment , patient proceed mobilization collection Adequate organ function define follow ( *unless clearly disease relate ) : 1 . Adequate renal function creatinine &lt; 2 x ULN 2 . Adequate hepatic function AST/ALT &lt; 3 x ULN , Total Bilirubin &lt; 3 x ULN , exception elevate indirect bilirubin attribute Gilbert 's syndrome hemolysis 3 . Adequate hematopoietic function Platelet ≥50 x 109/L ( without transfusion ) ANC ≥1.0 x 109/L 4 . LVEF &gt; 40 % ( MUGA echocardiogram ) 5 . Adequate pulmonary function DLCO &gt; 40 % Hypersensitivity JAK inhibitor Clinical evidence cirrhosis Leukemic transformation ( &gt; 20 % blast PB BM time prior HCT ) Platelet count &lt; 50 x 109/L Active uncontrolled infection History another malignancy within 5years date HCT except history basal cell squamous cell carcinoma skin PV ET Known HIV positive Woman childbearing potential unwilling unable use adequate contraception Pregnant nursing female Known active infection hepatitis A , B C virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>RUXOLITINIB</keyword>
	<keyword>Autologous stem cell transplant</keyword>
</DOC>